Ensysce Biosciences (ENSC) Institutional Ownership $5.40 -0.23 (-4.09%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$5.41 +0.01 (+0.19%) As of 02/21/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Ensysce Biosciences (NASDAQ:ENSC)CurrentInstitutional OwnershipPercentage5.63%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$3.95MNumber ofInstitutional Sellers(last 12 months)0 Get ENSC Insider Trade Alerts Want to know when executives and insiders are buying or selling Ensysce Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENSC Institutional Buying and Selling by Quarter Ensysce Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 Adage Capital Partners GP L.L.C.50,000$407K0.0%N/A3.817% 11/15/2024 Anson Funds Management LP983,518$236K0.0%N/A11.151% 11/15/2023 Sabby Management LLC96,973$134K0.1%-69.9%3.079% 8/14/2023 Anson Funds Management LP36,261$65K0.0%N/A2.833% 5/1/2023 Virtu Financial LLC13,433$65K0.0%N/A1.049% (Data available from 1/1/2016 forward) ENSC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENSC shares? During the previous two years, the following institutional investors and hedge funds held shares of Ensysce Biosciences shares: Adage Capital Partners GP L.L.C. ($407K), Anson Funds Management LP ($236K), and Sabby Management LLC ($134K), Virtu Financial LLC ($65K).Learn more on ENSC's institutional investors. What percentage of Ensysce Biosciences stock is owned by institutional investors? 5.63% of Ensysce Biosciences stock is owned by institutional investors. Learn more on ENSC's institutional investor holdings. Which institutional investors have been buying Ensysce Biosciences stock? The following institutional investors have purchased Ensysce Biosciences stock in the last 24 months: Anson Funds Management LP ($1.02M), Adage Capital Partners GP L.L.C. ($50K), and Virtu Financial LLC ($13.43K). How much institutional buying is happening at Ensysce Biosciences? Institutional investors have bought a total of 1,083,212 shares in the last 24 months. This purchase volume represents approximately $16.69M in transactions. Which Ensysce Biosciences major shareholders have been selling company stock? The following institutional investors have sold Ensysce Biosciences stock in the last 24 months: Sabby Management LLC ($225.33K). How much institutional selling is happening at Ensysce Biosciences? Institutional investors have sold a total of 225,325 shares in the last 24 months. This volume of shares sold represents approximately $4.66M in transactions. Related Companies MRNS Major Shareholders PMN Major Shareholders VRCA Major Shareholders SNYR Major Shareholders LEXX Major Shareholders XLO Major Shareholders BFRG Major Shareholders CMMB Major Shareholders PULM Major Shareholders RNXT Major Shareholders This page (NASDAQ:ENSC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
